close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Endeavor BioMedicines

News headline image
Endeavor BioMedicines Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
News headline image
First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
From Endeavor BioMedicines
Via Business Wire
News headline image
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
News headline image
Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline
From Endeavor BioMedicines
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today